Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2010

Sage and Pfizer Team Up on Cancer Research

  • Sage Bionetworks will partner with Pfizer to build, analyze, and exploit advanced network models of cancer. The companies hope the models will help identify therapeutic targets for oncology drug development as well as aid in evaluating the efficacy and safety of therapeutic candidates.

    Pfizer will provide research funding to Sage to analyze datasets from Pfizer, Sage, and the public domain. Sage will use genetic, molecular, and clinical information to create predictive computational disease models.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »